|
1
|
Hawkey CJ: COX-2 inhibitors. Lancet.
353:307–314. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chandrasekharan NV, Dai H, Roos KL,
Evanson NK, Tomsik J, Elton TS and Simmons DL: COX-3, a
cyclooxygenase-1 variant inhibited by acetaminophen and other
analgesic/antipyretic drugs: cloning, structure, and expression.
Proc Natl Acad Sci USA. 99:13926–13931. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsujii M and DuBois RN: Alterations in
cellular adhesion and apoptosis in epithelial cells overexpressing
prostaglandin endoperoxide synthase 2. Cell. 83:493–501. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsujii M, Kawano S and DuBois RN:
Cyclooxygenase-2 expression in human colon cancer cells increases
metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsujii M, Kawano S, Tsuji S, Sawaoka H,
Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced
by colon cancer cells. Cell. 93:705–716. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sheng H, Shao J, Morrow JD, Beauchamp RD
and DuBois RN: Modulation of apoptosis and Bcl-2 expression by
prostaglandin E2 in human colon cancer cells. Cancer Res.
58:362–366. 1998.PubMed/NCBI
|
|
7
|
Saikawa Y, Sugiura T, Toriumi F, Kubota T,
Suganuma K, Isshiki S, Otani Y, Kumai K and Kitajima M:
Cyclooxygenase-2 gene induction causes CDDP resistance in colon
cancer cell line, HCT-15. Anticancer Res. 24:2723–2728.
2004.PubMed/NCBI
|
|
8
|
Liu B, Qu L and Tao H: Cyclo-oxygenase 2
up-regulates the effect of multidrug resistance. Cell Biol Int.
34:21–25. 2009.PubMed/NCBI
|
|
9
|
Rolle CE, Sengupta S and Lesniak MS:
Mechanisms of immune evasion by gliomas. Adv Exp Med Biol.
746:53–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goldschmidt M, Peña L, Rasotto R and
Zappulli V: Classification and grading of canine mammary tumors.
Vet Pathol. 48:117–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spugnini EP, Porrello A, Citro G and Baldi
A: COX-2 over-expression in canine tumors: potential therapeutic
targets in oncology. Histol Histopathol. 20:1309–1312.
2005.PubMed/NCBI
|
|
12
|
Klopfleisch R, von Euler H, Sarli G, Pinho
SS, Gärtner F and Gruber AD: Molecular carcinogenesis of canine
mammary tumors: news from an old disease. Vet Pathol. 48:98–116.
2011. View Article : Google Scholar
|
|
13
|
Doré M: Cyclooxygenase-2 expression in
animal cancers. Vet Pathol. 48:254–265. 2011. View Article : Google Scholar
|
|
14
|
Pinho SS, Carvalho S, Cabral J, Reis CA
and Gärtner F: Canine tumors: a spontaneous animal model of human
carcinogenesis. Transl Res. 159:165–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Howe LR: Inflammation and breast cancer.
Cyclooxygenase/prostaglandin signaling and breast cancer. Breast
Cancer Res. 9:2102007. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Doré M, Lanthier I and Sirois J:
Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol.
40:207–212. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Queiroga FL, Pires I, Parente M, Gregório
H and Lopes CS: COX-2 over-expression correlates with VEGF and
tumour angiogenesis in canine mammary cancer. Vet J. 189:77–82.
2011. View Article : Google Scholar
|
|
18
|
Saito T, Tamura D and Asano R: Usefulness
of selective COX-2 inhibitors as therapeutic agents against canine
mammary tumors. Oncol Rep. 31:1637–1644. 2014.PubMed/NCBI
|
|
19
|
Kato M, Nishida S, Kitasato H, Sakata N
and Kawai S: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of
non-steroidal anti-inflammatory drugs: investigation using human
peripheral monocytes. J Pharm Pharmacol. 53:1679–1685. 2001.
View Article : Google Scholar
|
|
20
|
Sanderson RO, Beata C, Flipo RM, Genevois
JP, Macias C, Tacke S, Vezzoni A and Innes JF: Systematic review of
the management of canine osteoarthritis. Vet Rec. 164:418–424.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saito T, Dai T and Asano R: The hyaluronan
synthesis inhibitor 4-methylumbelliferone exhibits antitumor
effects against mesenchymal-like canine mammary tumor cells. Oncol
Lett. 5:1068–1074. 2013.PubMed/NCBI
|
|
22
|
Saito T, Tamura D, Nakamura T, Makita Y,
Ariyama H, Komiyama K, Yoshihara T and Asano R:
4-Methylumbelliferone leads to growth arrest and apoptosis in
canine mammary tumor cells. Oncol Rep. 29:335–342. 2013.
|
|
23
|
Saito T, Kawana H, Azuma K, Toyoda A,
Fujita H, Kitagawa M and Harigaya K: Fragmented hyaluronan is an
autocrine chemo-kinetic motility factor supported by the
HAS2-HYAL2/CD44 system on the plasma membrane. Int J Oncol.
39:1311–1320. 2011.PubMed/NCBI
|
|
24
|
Gurpinar E, Grizzle WE and Piazza GA:
COX-independent mechanisms of cancer chemoprevention by
anti-inflammatory drugs. Front Oncol. 3:1812013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kardosh A, Wang W, Uddin J, Petasis NA,
Hofman FM, Chen TC and Schönthal AH: Dimethyl-celecoxib (DMC), a
derivative of celecoxib that lacks cyclooxygenase-2-inhibitory
function, potently mimics the anti-tumor effects of celecoxib on
Burkitt’s lymphoma in vitro and in vivo. Cancer Biol Ther.
4:571–582. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luque I and Gélinas C: Rel/NF-kappa B
factors in oncogenesis. Semin Cancer Biol. 8:103–111. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Surh YJ, Chun KS, Cha HH, Han SS, Keum YS,
Park KK and Lee SS: Molecular mechanisms underlying chemopreventive
activities of anti-inflammatory phytochemicals: down-regulation of
COX-2 and iNOS through suppression of NF-kappa B activation. Mutat
Res. 480–481:243–268. 2001. View Article : Google Scholar
|
|
28
|
Takada Y, Bhardwaj A, Potdar P and
Aggarwal BB: Nonsteroidal anti-inflammatory agents differ in their
ability to suppress NF-kappaB activation, inhibition of expression
of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell
proliferation. Oncogene. 23:9247–9258. 2004.PubMed/NCBI
|
|
29
|
Baeuerle PA and Baltimore D: I kappa B: a
specific inhibitor of the NF-kappa B transcription factor. Science.
242:540–546. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tait SW and Green DR: Mitochondria and
cell death: outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Darzynkiewicz Z, Bruno S, Del Bino G,
Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of
apoptotic cells measured by flow cytometry. Cytometry. 13:795–808.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Igney FH and Krammer PH: Death and
anti-death: tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li P, Nijhawan D, Budihardjo I,
Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and
dATP-dependent formation of Apaf-1/caspase-9 complex initiates an
apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Menter DG, Schilsky RL and DuBois RN:
Cyclooxygenase-2 and cancer treatment: understanding the risk
should be worth the reward. Clin Cancer Res. 16:1384–1390. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Holmes MD, Chen WY, Li L, Hertzmark E,
Spiegelman D and Hankinson SE: Aspirin intake and survival after
breast cancer. J Clin Oncol. 28:1467–1472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Howe LR, Subbaramaiah K, Brown AM and
Dannenberg AJ: Cyclooxygenase-2: a target for the prevention and
treatment of breast cancer. Endocr Relat Cancer. 8:97–114. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ristimäki A, Sivula A, Lundin J, Lundin M,
Salminen T, Haglund C, Joensuu H and Isola J: Prognostic
significance of elevated cyclooxygenase-2 expression in breast
cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
|
|
40
|
Ranger GS, Thomas V, Jewell A and Mokbel
K: Elevated cyclooxygenase-2 expression correlates with distant
metastases in breast cancer. Anticancer Res. 24:2349–2351.
2004.PubMed/NCBI
|
|
41
|
Reader J, Holt D and Fulton A:
Prostaglandin E2 EP receptors as therapeutic targets in breast
cancer. Cancer Metastasis Rev. 30:449–463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Queiroga FL, Pires I, Lobo L and Lopes CS:
The role of Cox-2 expression in the prognosis of dogs with
malignant mammary tumours. Res Vet Sci. 88:441–445. 2010.
View Article : Google Scholar
|
|
43
|
Queiroga FL, Perez-Alenza MD, Silvan G,
Peña L, Lopes C and Illera JC: Cox-2 levels in canine mammary
tumors, including inf lammatory mammary carcinoma:
clinicopathological features and prognostic significance.
Anticancer Res. 25:4269–4275. 2005.PubMed/NCBI
|
|
44
|
Müller AC, Handrick R, Elsaesser SJ,
Rudner J, Henke G, Ganswindt U, Belka C and Jendrossek V:
Importance of Bak for celecoxib-induced apoptosis. Biochem
Pharmacol. 76:1082–1096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jendrossek V, Handrick R and Belka C:
Celecoxib activates a novel mitochondrial apoptosis signaling
pathway. FASEB J. 17:1547–1549. 2003.PubMed/NCBI
|
|
46
|
Liu X, Yue P, Zhou Z, Khuri FR and Sun SY:
Death receptor regulation and celecoxib-induced apoptosis in human
lung cancer cells. J Natl Cancer Inst. 96:1769–1780. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu X, Yue P, Schönthal AH, Khuri FR and
Sun SY: Cellular FLICE-inhibitory protein down-regulation
contributes to celecoxib-induced apoptosis in human lung cancer
cells. Cancer Res. 66:11115–11119. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Reginato MJ, Mills KR, Paulus JK, Lynch
DK, Sgroi DC, Debnath J, Muthuswamy SK and Brugge JS: Integrins and
EGFR coordinately regulate the pro-apoptotic protein Bim to prevent
anoikis. Nat Cell Biol. 5:733–740. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sun Y, Tang XM, Half E, Kuo MT and
Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic
susceptibility by inhibiting the cytochrome c-dependent apoptotic
pathway in human colon cancer cells. Cancer Res. 62:6323–6328.
2002.PubMed/NCBI
|
|
50
|
He Q, Luo X, Huang Y and Sheikh MS:
Apo2L/TRAIL differentially modulates the apoptotic effects of
sulindac and a COX-2 selective non-steroidal anti-inflammatory
agent in Bax-deficient cells. Oncogene. 21:6032–6040. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shao J, Evers BM and Sheng H:
Prostaglandin E2 synergistically enhances receptor tyrosine
kinase-dependent signaling system in colon cancer cells. J Biol
Chem. 279:14287–14293. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sonoshita M, Takaku K, Sasaki N, Sugimoto
Y, Ushikubi F, Narumiya S, Oshima M and Taketo MM: Acceleration of
intestinal polyposis through prostaglandin receptor EP2 in
Apc(Delta 716) knockout mice. Nat Med. 7:1048–1051. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nagatsuka I, Yamada N, Shimizu S, Ohira M,
Nishino H, Seki S and Hirakawa K: Inhibitory effect of a selective
cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int
J Cancer. 100:515–519. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Timoshenko AV, Xu G, Chakrabarti S, Lala
PK and Chakraborty C: Role of prostaglandin E2 receptors in
migration of murine and human breast cancer cells. Exp Cell Res.
289:265–274. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen Z, Hagler J, Palombella VJ, Melandri
F, Scherer D, Ballard D and Maniatis T: Signal-induced
site-specific phosphorylation targets I kappa B alpha to the
ubiquitin-proteasome pathway. Genes Dev. 9:1586–1597. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Seo KW, Coh YR, Rebhun RB, Ahn JO, Han SM,
Lee HW and Youn HY: Antitumor effects of celecoxib in COX-2
expressing and non-expressing canine melanoma cell lines. Res Vet
Sci. 96:482–486. 2014. View Article : Google Scholar : PubMed/NCBI
|
